Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

January 20, 2024

Primary Completion Date

July 1, 2025

Study Completion Date

June 1, 2029

Conditions
Breast CancerHER2-positive Breast Cancer
Interventions
DRUG

Dalcilib+letrozole+HP treatment group

"All participants received 150mg of darcilib once a day. Take it continuously for 21 days, then stop taking it for 7 days, with a treatment cycle of 28 days.~Letrozole 2.5mg once daily (premenopausal patients treated with OFS); Trastuzumab (8mg/kg first dose, 6mg/kg sequential) and Patuzumab (840mg first dose, 420mg/kg sequential) were administered intravenously every 3 weeks, or fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (1200 mg pertuzumab plus 600 mg trastuzumab loading dose in 15 mL, followed by 600 mg pertuzumab plus 600 mg trastuzumab maintenance doses in 10 mL), both administered every 3 weeks."

Trial Locations (1)

450008

RECRUITING

Henan cacer hospital, Henan

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV